Procarta Biosystems has received an award from CARB-X, potentially worth $9.2 million, for the development of antibiotic precision medicines. / read more /
A request has been made to the CHMP by the executive director of EMA to provide guidance on how to avoid the presence of nitrosamine impurities in human medicines. / read more /
The companies will develop and commercialize a Phase III cell therapy candidate for treating chronic low back pain in a deal worth potentially $1 billion. / read more /
Novo Nordisk has revealed the findings from an exploratory analysis of Phase IIIa clinical development program, demonstrating improved glycemic control with oral semaglutide. / read more /
The authors provide an introduction to aluminium adsorbed vaccines, review studies of antigen stability, and propose test methods for the analysis of aluminium vaccine release and stability analysis. / read more /
EMA is seeking ways to improve the effectiveness of its PRIME scheme, so that scientific innovations and new technologies more readily lead to novel medicines. / read more /
The editors explore novel technologies for the formulation, manufacture,
purification, and delivery of sterile small- and large-molecule drugs including single-use systems, facilities and equipment, contamination issues, and process analytics.
Register Now